EW - Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript
2024-02-06 21:05:23 ET
Edwards Lifesciences Corporation (EW)
Q4 2023 Earnings Conference Call
February 06, 2024, 05:00 PM ET
Company Participants
Mark Wilterding - Investor Relations and Treasurer
Bernard Zovighian - Chief Executive Officer
Scott Ullem - Chief Financial Officer
Daveen Chopra - Global Leader of TMTT
Larry Wood - Group President of TAVR and Surgical Structural Heart
Wayne Markowitz - Global Leader of Surgical Structural Heart
Conference Call Participants
Larry Biegelsen - Wells Fargo
Robbie Marcus - JPMorgan
Travis Steed - Bank of America
Patrick Wood - Morgan Stanley
Vijay Kumar - Evercore
Matt Taylor - Jefferies
Matt Miksic - Barclays
Chris Pasquale - Nephron Research
Danielle Antalffy - UBS
Presentation
Operator
Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mark Wilterding, Investor Relations and Treasurer. Thank you. You may begin.
Mark Wilterding
Thank you very much, Diego, and good afternoon, everyone. Thank you all for joining us.
With me on today's call is our CEO, Bernard Zovighian; and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Group President of TAVR and Surgical Structural Heart; Daveen Chopra, our Global Leader of TMTT; Wayne Markowitz, our Global Leader of Surgical Structural Heart; and Katie Szyman, our Global Leader of Critical Care.
Just after the close of regular trading, Edwards Lifesciences released fourth quarter 2023 financial results. During today's call, management will discuss those results included in the press release and accompanying financial statements and then use the remaining time for Q&A.
Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements include but are not limited to financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters, and foreign currency fluctuations. These statements speak only as of the date on which they were made and Edwards does not undertake any obligation to update them after today....
Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript